预约演示
更新于：2025-03-29
Imidafenacin
咪达那新
更新于：2025-03-29
概要
基本信息
药物类型 小分子化药 |
别名 Imidafenacin (JAN/INN)、KRP 197、KRP-197 + [9] |
作用方式 拮抗剂 |
作用机制 M1 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M1拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂) |
治疗领域 |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (2007-04-18), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H21N3O |
InChIKeySQKXYSGRELMAAU-UHFFFAOYSA-N |
CAS号170105-16-5 |
关联
48
项与 咪达那新 相关的临床试验CTR20242398
咪达那新片在中国健康受试者中的单中心、随机、开放、双周期、双交叉空腹及餐后状态下的生物等效性试验
ChiCTR2300070562
A randomized, open-label, two-formulation, two-period, crossover study of the bioequivalence of a single oral dose of Imidafenacin tablets in fasted and fed healthy Chinese subjects
CTR20202404
咪达那新片（0.1mg）在中国健康人群中空腹和餐后状态下单次给药的人体生物等效性临床试验
100 项与 咪达那新 相关的临床结果
登录后查看更多信息
100 项与 咪达那新 相关的转化医学
登录后查看更多信息
100 项与 咪达那新 相关的专利（医药）
登录后查看更多信息
158
项与 咪达那新 相关的文献（医药）2024-06-01Journal of Inclusion Phenomena and Molecular Recognition in Chemistry
Predictors for symptom improvement in overactive bladder patients treated with imidafenacin
作者: Jang, Kyoungha ; Lee, Jeong Zoo ; Park, Yangkyu ; Seong, Wooseop ; Kim, Seunghyeon ; Shin, Dong Gil ; Kim, Hyeon Woo ; Kim, Tae Nam
The objective of this investigation is to ascertain the determinants associated with the amelioration of symptoms in female patients suffering from overactive bladder (OAB) following treatment with 0.2 mg of imidafenacin.The study included 66 female OAB patients who had been prescribed a daily dose of 0.2 mg imidafenacin for a min. of 3 mo, spanning from March 2018 to June 2020.Various clin. parameters including age, coexistence of addnl. voiding symptoms, prior history of urol. surgeries, and responses to the Overactive Bladder Symptom Score questionnaire (OABSS), both pre- and post-initiation of imidafenacin therapy, were evaluated.The mean total OABSS scores recorded before and 3 mo subsequent to imidafenacin therapy were 8.36 ± 3.65 and 5.15 ± 3.22, resp.Following the 3-mo course of imidafenacin treatment, there was a statistically significant improvement in both the total OABSS score and the severity of OAB symptoms (p < 0.001 for both).Prior to treatment initiation, Group B (n = 38) exhibited significantly higher total OABSS scores and subscores compared to Group A (n = 28) (p < 0.05).Multivariable anal. identified the OABSS subscores for items 1 and 3 prior to treatment as significant predictors for the improvement of OAB severity subsequent to imidafenacin therapy (p = 0.046, OR 3.10, 95% CI 1.019-9.440 and p < 0.001, OR 2.77, 95% CI 1.671-4.587, resp.).Consequently, imidafenacin emerges as an efficacious therapeutic agent for alleviating OAB severity in female patients, with the OABSS subscores for items 1 and 3 prior to treatment initiation holding potential utility in predicting the efficacy of imidafenacin in managing OAB.
2024-06-01Drug metabolism and pharmacokinetics
Predicting muscarinic receptor occupancy in human bladder mucosa from urinary concentrations of antimuscarinic agents for overactive bladder
Article
作者: Yamada, Shizuo ; Tanaka, Shimako ; Akashita, Gaku ; Nakatani, Eriko ; Shiho, Mizuki ; Okura, Takashi
To assess the pharmacologically relevant and selective muscarinic receptor occupancy in the bladder mucosa, we considered not only plasma drug concentrations but also urinary drug concentrations. The purpose of this study was to predict muscarinic receptor occupancy in the human bladder mucosa based on urinary concentrations in response to clinical dosages of antimuscarinic agents used to treat overactive bladder. The calculated mean plasma or serum unbound steady state concentrations were 0.06-11 nM in clinical dosages of five antimuscarinic agents. Urinary concentrations calculated from the mean plasma or serum and renal clearance ranged between 19 nM and 2 μM, which were >10-fold higher than the Ki values for bladder muscarinic receptors excluding propiverine. Bladder mucosal muscarinic receptor occupancy estimated from the urinary concentrations and the Ki values was >90 % at a steady state in clinical dosages of five antimuscarinic agents. The bladder muscarinic receptor occupancy was higher than that in the parotid gland calculated based on the mean plasma or serum unbound concentrations and Ki values for muscarinic receptors in the parotid gland. These results suggest that sufficient and selective muscarinic receptor occupancy by antimuscarinic agents, to exert pharmacological effects, in the bladder mucosa can be predicted using urinary concentrations.
2024-04-19ACS chemical biology
Characterization of Chemical Interactions between Clinical Drugs and the Oral Bacterium, Corynebacterium matruchotii, via Bioactivity-HiTES
Article
作者: Kim, Chung Sub ; Kim, Ki Hyun ; Kim, Jonghwan ; Lee, Seoung Rak ; Song, Jeongwon ; Lee, Gyu Sung ; Park, Sehwan ; Lee, Bum Soo ; Lee, Da Yeong
In the field of natural product research, the rediscovery of already-known compounds is one of the significant issues hindering new drug development. Recently, an innovative approach called bioactivity-HiTES has been developed to overcome this limitation, and several new bioactive metabolites have been successfully characterized by this method. In this study, we applied bioactivity-HiTES to Corynebacterium matruchotii, the human oral bacterium, with 3120 clinical drugs as potential elicitors. As a result, we identified two cryptic metabolites, methylindole-3-acetate (MIAA) and indole-3-acetic acid (IAA), elicited by imidafenacin, a urinary antispasmodic drug approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). MIAA showed weak antibacterial activity against a pulmonary disease-causing Mycobacterium conceptionense with an IC50 value of 185.7 μM. Unexpectedly, we also found that C. matruchotii metabolized fludarabine phosphate, a USFDA-approved anticancer drug, to 2-fluoroadenine which displayed moderate antibacterial activity against both Bacillus subtilis and Escherichia coli, with IC50 values of 8.9 and 20.1 μM, respectively. Finally, acelarin, a prodrug of the anticancer drug gemcitabine, was found to exhibit unreported antibacterial activity against B. subtilis with an IC50 value of 33.6 μM through the bioactivity-HiTES method as well. These results indicate that bioactivity-HiTES can also be applied to discover biotransformed products in addition to finding cryptic metabolites in microbes.
1
项与 咪达那新 相关的新闻（医药）2024-01-15
·信狐药迅
100 项与 咪达那新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱过度活动症 | 日本 | 2007-04-18 | |
| 膀胱过度活动症 | 日本 | 2007-04-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 尿频 | 申请上市 | 俄罗斯 | 2022-01-30 | |
| 急迫性尿失禁 | 临床1期 | 中国 | 2015-06-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 300 | 鬱淵繭遞糧淵繭艱襯構(鏇壓簾襯艱簾鹽築襯艱) = 網衊蓋齋餘夢糧壓選廠 獵壓鏇觸齋淵蓋鹽齋簾 (遞淵夢蓋艱憲範鏇築窪, 2.2) 更多 | 非劣 | 2019-06-01 | |||
鬱淵繭遞糧淵繭艱襯構(鏇壓簾襯艱簾鹽築襯艱) = 繭膚獵齋獵齋網繭糧網 獵壓鏇觸齋淵蓋鹽齋簾 (遞淵夢蓋艱憲範鏇築窪, 1.8) 更多 | |||||||
临床3期 | 300 | (Uritos®) | 窪窪廠壓鹹襯構餘繭壓(鏇繭淵壓淵鏇壓齋餘蓋) = 糧繭壓積繭選夢鹽壓網 積繭艱繭醖夢壓築夢壓 (餘廠衊鹹淵餘獵鬱構鏇, 3.5) 更多 | - | 2019-05-21 | ||
(Urotol®) | 窪窪廠壓鹹襯構餘繭壓(鏇繭淵壓淵鏇壓齋餘蓋) = 積膚網製鹽憲廠糧壓積 積繭艱繭醖夢壓築夢壓 (餘廠衊鹹淵餘獵鬱構鏇, 2.7) 更多 | ||||||
临床4期 | 649 | (Mirabegron + Solifenacin) | 製憲醖範鹹積憲觸鹹鏇 = 範膚築蓋鹹醖餘衊遞壓 遞繭繭遞醖齋願選艱構 (構糧鬱顧膚獵夢簾獵製, 構製齋鬱蓋範廠鏇襯顧 ~ 膚遞淵壓簾淵築憲顧餘) 更多 | - | 2018-12-24 | ||
(Mirabegron + Propiverine) | 製憲醖範鹹積憲觸鹹鏇 = 壓觸構獵鹽遞鹽醖夢網 遞繭繭遞醖齋願選艱構 (構糧鬱顧膚獵夢簾獵製, 簾積衊鹹醖醖襯網憲淵 ~ 獵簾糧壓鹽齋鏇願廠餘) 更多 | ||||||
N/A | 308 | 願襯齋窪鏇選顧繭選獵(壓製鏇艱餘鬱壓鑰糧積) = 淵製顧顧顧衊淵願繭鏇 膚窪網醖憲膚醖廠窪範 (鹹積壓膚網構艱鏇遞蓋, 1.47 ~ 2.74) 更多 | 积极 | 2013-10-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用